Pharmacia Ab

Astra Ab

Astrazeneca Ab

Kabi Pharmacia Ab

Hammercap Ab

Lars-Inge Olsson

Martin Haraldsson

Leif G Ahrgren

Thomas Berglindh

Hubert Agback

Arne T Eek

Anna-Lena Ask

Rune Sandberg

Per Lennart Lindberg

Rolf Bergman

Erwan Arzel

Goran Smedegard

Goran Smedegangrd

G Oran Smedegangrd

Arne Eek

The present invention relates to novel boron comprising compounds, to pharmaceutical compositions comprising said compounds, to the therapeutic use of said compounds, and to a process for preparation of said compounds. The compounds are useful in boron neutron capture therapy (BNCT). 

Boron compounds useful in BNCT

The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.

Compounds useful as antibacterial agents

New compounds of the formula (A) ##STR1## a process for their preparation and their use in the manufacture of pharmaceutical preparations. The new compounds have both local anaesthetic and analgesic effect.

Compounds with analgesic and local anaesthetic effect

A compound of the formula Het--NR--SO.sub.2 --Ph.sup.2 --A--Ph.sup.1 (COOH)(OH) and tautomic form, salts, solvates, C.sub.1-6 alkyl esters and pharmaceutical compositions of the compound. Ph.sup.1 and Ph.sup.2 are benzene rings with the proviso that carboxy and hydroxy are ortho to one another. Het includes an optionally substituted heterocyclic ring which includes conjugated double bonds and binds to nitrogen in NR. The compound is characterized in that A is a bridge which is stable against reduction because it is not azo, and in that R is hydrogen or lower alkyl. The invention also includes the preparation of the compound and its use as a drug, particularly for treating autoimmune diseases.

N-heterocyclic substituted salicylic acids

Substituted salicylic acids

A compound of the formula Het--NR--SO.sub.2 --Ph.sup.2 --A--Ph.sup.1 (COOH)(OH) and tautomeric form, salts, solvates, C.sub.1-6 alkyl esters and pharmaceutical compositions of the compound. Ph.sup.1 and Ph.sup.2 are benzene rings with the proviso that carboxy and hydroxy are ortho to one another. Het includes an optionally substituted heterocyclic ring which includes conjugated double bonds and binds to nitrogen in NR. The compound is characterized in that A is a bridge which is stable against reduction because it is not azo, and in that R is hydrogen or lower alkyl. The invention also includes the preparation of the compound and its use as a drug, particularly for treating autoimmune diseases.

Compounds containing an amino salicylic acid moiety linked to a

Growing community of inventors

Sodertalje, Sweden

Lars-Inge Olsson